**Brain morphometry is not associated with non-motor outcomes

after deep brain stimulation in Parkinson's disease**

Philipp Alexander Loehrer, MD¹, Wibke Schumacher, MD^{2,3}, Stefanie T. Jost, PhD², Monty

Silverdale.

- **after deep brain stimulation in Parkinson's disease**

2 Philipp Alexander Loehrer, MD¹, Wibke Schumacher, MD^{2,3}, Stefanie T. Jost, PhD²

2 Silverdale, MD⁴, Jan Niklas Petry-Schmelzer, MD², Anna Sauerbier, MD/PhD Philipp Alexander Loehrer, MD¹, Wibke Schumacher, MD^{2,3}, Stefanie T. Jost, PhD²
- 3 Philipp Alexander Loehrer, MD¹, Wibke Schumacher, MD^{2,3}, Stefanie T. Jost, PhD², Monty

4 Silverdale, MD⁴, Jan Niklas Petry-Schmelzer, MD², Anna Sauerbier, MD/PhD^{2,5}, Alexandra

5 Gronostay, MD², Veerle Vi Silverdale, MD⁴, Jan Niklas Petry-Schmelzer, MD², Anna Sauerbier, MD/PhD^{2,5}
- 4 Silverdale, MD⁴, Jan Niklas Petry-Schmelzer, MD², Anna Sauerbier, MD/PhD^{2,5}, Alexandra
5 Gronostay, MD², Veerle Visser-Vandewalle, MD/PhD⁶, Gereon R. Fink, MD^{2,7}, Julian Evans
6 MD⁸, Max Krause, MD^{2,9}, A Gronostay, MD², Veerle Visser-Vandewalle, MD/PhD⁶, Gereon R. Fink, MD^{2,7}
- $\mathrm{MD}^8,$ Max Krause, MD $^{2,9},$ Alexandra Rizos, PhD 5, Angelo Antonini, MD 10
- Ashkan, $MD¹¹$, Pablo Martinez-Martin, $MD/PhD¹²$, Christian Gaser, Ph $D^{13,14,15,16}$, K. Ray
- 5 Gronostay, MD², Veerle Visser-Vandewalle, MD/PhD⁰, Gereon R. Fink, MD^{2,1}, Julian Evans,
6 MD⁸, Max Krause, MD^{2,9}, Alexandra Rizos, PhD⁵, Angelo Antonini, MD¹⁰, Keyoumars
7 Ashkan, MD¹¹, Pablo Martinez-Ma MD^8 , Max Krause, MD^{2,9}, Alexandra Rizos, PhD³, Angelo Antonini, MD¹⁰, Keyoumars

Ashkan, MD¹¹, Pablo Martinez-Martin, MD/PhD¹², Christian Gaser, PhD^{13,14,15,16}, K. Ra

Chaudhuri, MD/PhD^{5,17}, Lars Timme Ashkan, MD¹¹, Pablo Martinez-Martin, MD/PhD¹², Christian Gaser, PhD^{13,14,15,16}, K. Ray

8 Chaudhuri, MD/PhD^{5,17}, Lars Timmermann, MD¹, Carlos Baldermann, MD^{2*}, Haidar S.

9 Dafsari, MD^{2*}

0 On behalf of EURO Chaudhuri, MD/PhD^{5,17}, Lars Timmermann, MD¹, Carlos Baldermann, MD²
- Dafsari, MD^{2*}
- 8 Chaudhuri, MD/PhD^{5,17}, Lars Timmermann, MD¹, Carlos Baldermann, MD²*, Haidar S.

9 Dafsari, MD^{2*}

0 On behalf of EUROPAR and the International Parkinson and Movement Disorders Society

11 Non-Motor Parkinson's D 0
1
2 10 On behalf of EUROPAR and the International Parkinson and Movement Disorders Society

11 Non-Motor Parkinson's Disease Study Group.

12 ¹Department of Neurology, Philipps-University Marburg, Marburg, Germany
-
-
- ¹Department of Neurology, Philipps-University Marburg, Marburg, Germany
- 11 Non-Motor Parkinson's Disease Study Group.
12
¹Department of Neurology, Philipps-Universit.
²University of Cologne, Faculty of Medicine a --
13
14
15
16 2
- ¹Department of Neurology, Philipps-University Marburg, Marburg, Germany

²University of Cologne, Germany

³University of Cologne, Germany

³University of Cologne, Faculty of Medicine and University Hospital Cologne ²University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

15 Neurology, Cologne, Germany

³University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

17 15 Neurology, Cologne, Germany

³University of Cologne, Faculty

¹⁷ Pediatrics, Cologne, Germany

⁴Department of Neurology and

Manchester, United Kingdom

⁵National Parkinson Foundation 3
- ⁴Department of Neurology and Neurosurgery, Salford Royal Foundation Thrust, Greater
- ³University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

Pediatrics, Cologne, Germany

⁴Department of Neurology and Neurosurgery, Salford Royal Foundation Thrust, Greater

Manchester, 17 Pediatrics, Cologne, Germany

⁴ Department of Neurology and

19 Manchester, United Kingdom

⁵ National Parkinson Foundatio

121 United Kingdom

122 ⁶ University of Cologne, Facult ⁴ Department of Neurology and Neurosurgery, Salford Royal Foundation Thrust, Greater

19 Manchester, United Kingdom

⁵ National Parkinson Foundation Centre of Excellence, King's College Hospital, London,

121 ⁶ Unive 19 Manchester, United Kingdom

20 ⁵National Parkinson Foundatio

21 United Kingdom

22 ⁶University of Cologne, Facult

21 ⁷Cognitive Neurosciance Instituted 5 ²National Parkinson Foundation Centre of Excellence, King's College Hospital, London,

²¹ University of Cologne, Faculty of Medicine and University Hospital Cologne, Departme

⁶University of Cologne, Faculty of Medic
- ⁶University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of
-
- 21 United Kingdom

22 ⁶University of Co

23 Stereotactic and H

⁷Cognitive Neuro

25 Jülich, Jülich, Ge

⁸Department of N 7
-
- ⁸Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust,
- ^oUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of
23 Stereotactic and Functional Neurosurgery, Cologne, Germany
⁷Cognitive Neuroscience, Institute of Neuroscience and Medicine (23 Stereotactic and Functional Neurosurgery, Cologne, Germany

⁷Cognitive Neuroscience, Institute of Neuroscience and Medic

⁷Cognitive Neuroscience, Institute of Neuroscience and Medic

⁸Department of Neurology and ⁷Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center

25 Jülich, Jülich, Germany

⁸Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust,

27 Manchester Academ 25 Jülich, Jülich, Germany
26 ⁸Department of Neurolo
27 Manchester Academic F
28 United Kingdom
29 ⁹University of Cologne,
30 Radiation Oncology, Cy ⁸Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust,

27 Manchester Academic Health Science Centre, University of Manchester, Greater Mar

⁹University of Cologne, Faculty of Medicine and Unive Manchester Academic Health Science Centre, University of Manchester, Greater Manchester,

28 University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

29 ⁹University of Cologne, Gener, Co
- 9
-
- 28 United Kingdom
29 ⁹University of Co
30 Radiation Oncolo
31 ¹⁰Department of M
¹¹Department of M Radiation Oncology, Cyberknife Center, Cologne, Germany

¹⁰Department of Neuroscience, University of Padua, Padua, I

¹¹Department of Neurosurgery, King's College Hospital, Lon

¹²Center for Networked Biomedical Rese 10
- ¹⁰Department of Neuroscience, University of Padua, Padua, Italy
³¹ ¹¹Department of Neurosurgery, King's College Hospital, London,
³³ ¹²Center for Networked Biomedical Research in Neurodegenerati
³⁴ Carlos III I
- ⁹University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

Radiation Oncology, Cyberknife Center, Cologne, Germany

¹⁰Department of Neuroscience, University of Padua, Padua, Italy

¹¹ ¹¹ Department of Neurosurgery, King's College Hospital, London, United Kingdom

¹² Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBE

Carlos III Institute of Health. Madrid, Spain.
 NOTE: 12 ¹² Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED),
Carlos III Institute of Health. Madrid, Spain.
NOTE: This preprint reports new research that has not been certified by peer review an
- 34 Carlos III Institute of Health. Madrid, Spain.
NOTE: This preprint reports new research that has not been cert

- ¹³Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
-
- ¹⁴Department of Neurology, Jena University Hospital, Jena, Germany
- ¹⁵German Center for Mental Health (DZPG), Site Jena-Magdeburg-Halle
- ¹³Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.

2 Department of Neurology, Jena University Hospital, Jena, Germany

¹⁴Department of Neurology, Jena University Hospital, Jena, Ger 2 Department of Neurology, Jena University Hospital, Jena, Germany

¹⁴Department of Neurology, Jena University Hospital, Jena, German

¹⁵German Center for Mental Health (DZPG), Site Jena-Magdeburg-F

¹⁶Center for Int ¹⁴Department of Neurology, Jena University Hospital, Jena, Germany

¹⁵German Center for Mental Health (DZPG), Site Jena-Magdeburg-Ha

¹⁶Center for Intervention and Research on adaptive and maladaptive b

mental healt ¹⁵German Center for Mental Health (DZPG), Site Jena-Magdeburg-Halle

¹⁶Center for Intervention and Research on adaptive and maladaptive brain

mental health (C-I-R-C), Jena-Magdeburg-Halle

¹⁷The Maurice Wohl Clinic ¹⁶Center for Intervention and Research on adaptive and maladaptive brain Circuits underlying

nental health (C-I-R-C), Jena-Magdeburg-Halle

¹⁷The Maurice Wohl Clinical Neuroscience Institute, King's College London, Lo
- 6 mental health (C-I-R-C), Jena-Magdeburg-Halle

¹⁷The Maurice Wohl Clinical Neuroscience Instit

Kingdom

9 *Contributed equally

0 17 ¹The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United

⁸ Kingdom

⁹ <u>*Contributed equally</u>

0

1 Corresponding authors:
- 8 Kingdom
9 <u>*Contribu</u>
0
1 <u>Correspor</u>
-
- 9 *Contributed equally
10
11 Corresponding authors:
12 Philipp Loehrer
- --
11
12
- 11 Corresponding authors:

12 Philipp Loehrer

13 Department of Neurolog
- 12 Philipp Loehrer Haidar S. Dafsari

13 Department of Neurology

14 Philipps-University Marburg University Hospital Cologne 13 Department of Neurology

14 Philipps-University Marburg

15 Baldinger Str.

16 Baldinger Str.

16 Repenerstr. 62 14 Philipps-University Marburg University Hospital Cologne

15 Baldinger Str. Kepenerstr. 62

16 35043 Marburg, Germany 50937 Cologne, Germany
-
- 15 Baldinger Str. Kepenerstr. 62

16 35043 Marburg, Germany 50937 Cologne, Germany

17 Tel: +49 6421 5866419 Tel.: +49 221 478 37445
-
- 16 35043 Marburg, Germany 50937 Cologne, Germany

17 Tel: +49 6421 5866419

18 Email: loehrer@staff.uni-marburg.de Email: haidar.dafsari@uk-koeln.de
-

Number of References: 41
24 **Character count title:** 111
25 **Keywords:** non-motor symptoms, Parkinson's
26 morphometry
27 **Character count title:**¹¹¹
25 **Keywords:** non-motor symptoms, Parkinson's d
26 morphometry
27 **Keywords:** non-motor symptoms, Parkinson's disease, deep brain stimulation, voxel-based
26 morphometry
27 26 morphometry
27
28

 -28

Abstract

2 Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy in

2 Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy in

3 advanced Parkinson's dis 2 Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy in
3 advanced Parkinson's disease (PD). Motor and non-motor outcomes, however, show
4 considerable inter-individual variability. Morph 3 advanced Parkinson's disease (PD). Motor and non-motor outcomes, however, show
considerable inter-individual variability. Morphometry-based metrics have recently received
increasing attention to predict treatment effects 4 considerable inter-individual variability. Morphometry-based metrics have recently received
increasing attention to predict treatment effects. As evidence for the prediction of non-motor
outcomes is limited, we sought to 5 increasing attention to predict treatment effects. As evidence for the prediction of non-motor
6 outcomes is limited, we sought to investigate the association between metrics of voxel-based
7 morphometry and short-term n 6 outcomes is limited, we sought to investigate the association between metrics of voxel-based
morphometry and short-term non-motor outcomes following STN-DBS in this prospective
open-label study. 49 PD patients underwent 7 open-label study. 49 PD patients underwent structural MRI and a comprehensive clinical
3 assessment at preoperative baseline and 6-month follow-up. Voxel-based morphometry was
10 used to assess associations between cereb 11 multiple comparisons using a permutation-based approach. We replicated existing results 9 assessment at preoperative baseline and 6-month follow-up. Voxel-based morphometry was
0 used to assess associations between cerebral volume and non-motor outcomes corrected for
1 multiple comparisons using a permutation 10 used to assess associations between cerebral volume and non-motor outcomes corrected for
11 multiple comparisons using a permutation-based approach. We replicated existing results
12 associating atrophy of the superior multiple comparisons using a permutation-based approach. We replicated existing results
associating atrophy of the superior frontal cortex with subpar motor outcomes. Non-motor
outcomes, however, were not associated with m 12 associating atrophy of the superior frontal cortex with subpar motor outcomes. Non-motor
13 outcomes, however, were not associated with morphometric features, limiting its use as a
14 marker to inform patient selection 13 outcomes, however, were not associated with morphometric features, limiting its use as a
14 marker to inform patient selection and holistic preoperative counselling.
15 14 marker to inform patient selection and holistic preoperative counselling.
15

1 **Introduction**
2 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for
3 the treatment of motor and non-motor symptoms in advanced Parkinson's disease (PD).¹⁻³
4 Despite its well-e 2 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for

2 the treatment of motor and non-motor symptoms in advanced Parkinson's disease (PD).¹⁻³

2 Despite its well-established effe the treatment of motor and non-motor symptoms in advanced Parkinson's disease (PD). $^{1-3}$ 4
5
6 94 Despite its well-established effects at the group level, individual symptom relief varies
5 significantly, complicating preoperative patient selection and counselling.⁴ To predict
6 outcomes and support preoperative m significantly, complicating preoperative patient selection and counselling.⁴ significantly, complicating preoperative patient selection and counselling.⁴ To predict
outcomes and support preoperative management, neuroimaging-based biomarkers using
advanced imaging technologies, such as tractograph 6 outcomes and support preoperative management, neuroimaging-based biomarkers using
advanced imaging technologies, such as tractography and functional MRI, have proven
useful.^{4,5} Their widespread clinical application, ho 27 advanced imaging technologies, such as tractography and functional MRI, have proven
18 useful.^{4,5} Their widespread clinical application, however, is limited by the need for additional
19 and sometimes time-consuming s useful. 4,5 useful.^{4,5} Their widespread clinical application, however, is limited by the need for additional
and sometimes time-consuming scanning protocols and the expertise to analyse and translate
their results.⁶ Therefore, the and sometimes time-consuming scanning protocols and the expertise to analyse and translate
their results.⁶ Therefore, the association of postoperative outcomes with metrics based on T1-
weighted sequences obtained in cli their results.⁶ 10 their results.⁶ Therefore, the association of postoperative outcomes with metrics based on T1-
11 weighted sequences obtained in clinical routine during surgical planning has been
12 investigated. Particularly, analys weighted sequences obtained in clinical routine during surgical planning has been
investigated. Particularly, analyses focussing on morphometric tissue features, such as voxel-
based morphometry (VBM), have lately received investigated. Particularly, analyses focussing on morphometric tissue features, such as voxel-
based morphometry (VBM), have lately received increasing attention to monitor clinical
progression and treatment effects.⁶ In based morphometry (VBM), have lately received increasing attention to monitor clinical
progression and treatment effects.⁶ In a recent meta-analysis including 1253 patients enrolled
in 24 studies, Wang and colleagues ide progression and treatment effects.⁶ progression and treatment effects.⁶ In a recent meta-analysis including 1253 patients enrolled
in 24 studies, Wang and colleagues identified specific areas whose morphometric features
were associated with outcomes follow in 24 studies, Wang and colleagues identified specific areas whose morphometric features
16 were associated with outcomes following STN-DBS.⁶ Here, atrophy of the motor cortex and
17 thalamus was associated with below-av were associated with outcomes following STN-DBS.⁶ were associated with outcomes following STN-DBS.⁸ Here, atrophy of the motor cortex and
thalamus was associated with below-average improvement in motor symptoms. On the other
hand, outcome prediction of non-motor symptom thalamus was associated with below-average improvement in motor symptoms. On the other
hand, outcome prediction of non-motor symptoms has received little attention, with studies
focusing on cognitive decline and immediate hand, outcome prediction of non-motor symptoms has received little attention, with studies
focusing on cognitive decline and immediate psychiatric alterations such as postoperative
confusion, delirium, and impulsivity.⁶ 19 focusing on cognitive decline and immediate psychiatric alterations such as postoperative

20 confusion, delirium, and impulsivity.⁶ Poor outcomes in verbal memory were associated with

21 hippocampal atrophy at basel confusion, delirium, and impulsivity.⁶ confusion, delirium, and impulsivity.⁶ Poor outcomes in verbal memory were associated with
hippocampal atrophy at baseline, while immediate psychiatric complications were related to
caudal middle frontal cortex atrophy. hippocampal atrophy at baseline, while immediate psychiatric complications were related to
caudal middle frontal cortex atrophy.⁶ As STN-DBS is associated with beneficial short-term
outcomes in a range of non-motor sympt caudal middle frontal cortex atrophy.⁶ As STN-DBS is associated with beneficial short-term
outcomes in a range of non-motor symptoms such as sleep/fatigue, attention/memory, and
mood/apathy,^{7,8} in the present study, we 23 outcomes in a range of non-motor symptoms such as sleep/fatigue, attention/memory, and
24 mood/apathy,^{7,8} in the present study, we sought to explore the association between a large
25 spectrum of non-motor symptoms a mood/apathy,^{7,8} 24 mood/apathy,^{7,8} in the present study, we sought to explore the association between a large spectrum of non-motor symptoms and volumetric properties. 25 spectrum of non-motor symptoms and volumetric properties.

1 **Results**
2 **Clinical o**
3 Forty-nine
4 month follo 2 **Clinical outcomes**
3 Forty-nine patients w
4 month follow-up, the
5 PDQ-8 SI (p<.001, 3 Forty-nine patients with PD (31 males, mean age 64.5 ± 8.2 years) were enrolled. At the six
4 month follow-up, the following scales improved: NMSS total score (p=.006, Cohen's d=.46),
5 PDQ-8 SI (p<.001, Cohen's d=.52 4 month follow-up, the following scales improved: NMSS total score (p=.006, Cohen's d=.46),

9 PDQ-8 SI (p<.001, Cohen's d=.52), UPDRS III (p=.023, Cohen's d=.45), SCOPA-M

4 activities of daily living (p<.001, Cohen's d= 5 PDQ-8 SI (p<.001, Cohen's d=.52), UPDRS III (p=.023, Cohen's d=.45), SCOPA-M
activities of daily living (p<.001, Cohen's d=.56), SCOPA-M motor complications (p<.001,
Cohen's d=.85), and LEDD (p<.001, Cohen's d=1.06). An 6 activities of daily living (p<.001, Cohen's d=.56), SCOPA-M motor complications (p<.001,
Cohen's d=.85), and LEDD (p<.001, Cohen's d=1.06). Analysis of NMSS domains revealed
beneficial effects of STN-DBS on sleep/fatigu 7 Cohen's d=.85), and LEDD (p<.001, Cohen's d=1.06). Analysis of NMSS domains revealed
beneficial effects of STN-DBS on sleep/fatigue (p=.003, Cohen's d=.55), perceptual
problems/hallucinations (p=.023, Cohen's d=.39), ur 8 beneficial effects of STN-DBS on sleep/fatigue (p=.003, Cohen's d=.55), perceptual
9 problems/hallucinations (p=.023, Cohen's d=.39), urinary symptoms (p=.023, Cohen's
0 d=.35), and miscellaneous symptoms (p<.001, Cohen 9 problems/hallucinations (p=.023, Cohen's d=.39), urinary symptoms (p=.023, Cohen's d=.35), and miscellaneous symptoms (p<.001, Cohen's d=.68). Longitudinal changes of clinical outcomes are reported in Table 1.
2 d=.35), and miscellaneous symptoms (p<.001, Cohen's d=.68). Longitudinal changes of
clinical outcomes are reported in Table 1.
12
Association of morphometry surrogates and postoperative motor symptom

11 clinical outcomes are reported in Table 1.
12
13 Association of morphometry surr
14 change --
13
14
15

13 **Association of morphometry surrogates and postoperative motor symptom
14 change**
15 A multiple regression analysis assessed the relationship between motor response to STN-DBS
16 and morphometry surrogates. Following a 14 **change**
15 A multip
16 and mor
17 approach 15 A multiple regression analysis assessed the relationship between motor response to STN-DBS
16 and morphometry surrogates. Following a threshold-free cluster enhancement (TFCE)
17 approach to correct for multiple compari 16 and morphometry surrogates. Following a threshold-free cluster enhancement (TFCE) approach to correct for multiple comparisons, a cluster within the bilateral superior frontal cortex showed a positive association with c 17 approach to correct for multiple comparisons, a cluster within the bilateral superior frontal
18 cortex showed a positive association with changes in postoperative motor function.
19 Association of morphometry surrogate

18 cortex showed a positive association with changes in postoperative motor function.
19
20 Association of morphometry surrogates and postoperative non-motor
21 change --
20
21
22

20 **Association of morphometry surrogates and postoperative non-motor symptom**
21 **change**
22 No significant associations were observed between morphometry surrogates and change
23 scores of NMSS-T and NMSS-domains, follow 21 **change**
22 No sign:
23 scores of
24 comparis 22 No significant associations were observed between morphometry surrogates and change
23 scores of NMSS-T and NMSS-domains, following a TFCE approach to correct for multiple
24 comparisons.
25 23 scores of NMSS-T and NMSS-domains, following a TFCE approach to correct for multiple
24 comparisons.
25 24 comparisons.
25

Discussion
2 In the present study, we investigated the association between brain morphometric features and
2 changes in clinical outcomes following STN-DBS in PD. We replicated findings that impaired
4 integrity of the f 2 In the present study, we investigated the association between brain morphometric features and
2 changes in clinical outcomes following STN-DBS in PD. We replicated findings that impaired
2 integrity of the frontal cortex 3 changes in clinical outcomes following STN-DBS in PD. We replicated findings that impaired
4 integrity of the frontal cortex is associated with subpar improvement in motor symptoms
5 following STN-DBS. In contrast, chang integrity of the frontal cortex is associated with subpar improvement in motor symptoms
following STN-DBS. In contrast, changes in non-motor symptoms were not associated with
features of brain morphometry.
Employing a whol 5 following STN-DBS. In contrast, changes in non-motor symptoms were not associated with
6 features of brain morphometry.
7 Employing a whole brain voxel-based morphometry analysis, we identified an association
8 between r

6 features of brain morphometry.
7 Employing a whole brain voxe
8 between reduced volume of th
9 after neurostimulation in PD. T 10 after neurostimulation in PD. This finding is consistent with previous studies demonstrating
10 an association between poor motor outcomes and reduced cortical thickness and a diminished 18 between reduced volume of the bilateral superior frontal cortex and poor motor outcomes

29 after neurostimulation in PD. This finding is consistent with previous studies demonstrating

20 an association between poor mo 9 after neurostimulation in PD. This finding is consistent with previous studies demonstrating
1 an association between poor motor outcomes and reduced cortical thickness and a diminished
1 volume of this region.^{9,10} Imp 10 an association between poor motor outcomes and reduced cortical thickness and a diminished
11 volume of this region.^{9,10} Importantly, the superior frontal cortex comprises the critical
12 structures of the motor netwo volume of this region. $9,10$ 11 volume of this region.^{9,10} Importantly, the superior frontal cortex comprises the critical
12 structures of the motor network for movement generation and control.^{9,11,12} Information
13 processing within this networ structures of the motor network for movement generation and control.^{9,11,12} Information structures of the motor network for movement generation and control.^{9,11,12} Information
13 processing within this network is altered in PD and modulated by dopaminergic replacement
14 therapy and DBS, result processing within this network is altered in PD and modulated by dopaminergic replacement
therapy and DBS, resulting in improved motor function.^{13,14} In STN-DBS, this modulation is
in part elicited by antidromic conveyan therapy and DBS, resulting in improved motor function.^{13,14} therapy and DBS, resulting in improved motor function.^{13,14} In STN-DBS, this modulation is
in part elicited by antidromic conveyance of stimulation signals via the hyperdirect pathway
that directly links the subthalamic in part elicited by antidromic conveyance of stimulation signals via the hyperdirect pathway
16 that directly links the subthalamic nucleus to structures of the motor network.¹⁵ Consequently,
17 integrity of the frontal that directly links the subthalamic nucleus to structures of the motor network.¹⁵ integrity of the frontal cortex seems crucial for STN-DBS to exert its effects and might serve
as a marker to predict motor response after DBS surgery. In future studies, larger sample sizes
in multicentre cohorts are need 17 integrity of the frontal cortex seems crucial for STN-DBS to exert its effects and might serve
18 as a marker to predict motor response after DBS surgery. In future studies, larger sample sizes
19 in multicentre cohorts 18 as a marker to predict motor response after DBS surgery. In future studies, larger sample sizes
19 in multicentre cohorts are needed to define patient-specific thresholds and thus implement
120 bilateral superior fronta

19 bilateral superior frontal cortex volume as a biomarker for individual outcome prediction.

19 Contrary to our expectations, there were no associations between morphometric features and

19 Dostoperative changes in non-20 bilateral superior frontal cortex volume as a biomarker for individual outcome prediction.
21 Contrary to our expectations, there were no associations between morphometric features
22 postoperative changes in non-motor 21 Contrary to our expectations, there were no associations between morphometric features and
22 postoperative changes in non-motor symptoms. The effect sizes of postoperative motor and
23 non-motor symptom change were sim postoperative changes in non-motor symptoms. The effect sizes of postoperative motor and
non-motor symptom change were similar and we observed the aforementioned association
between motor symptoms and brain morphometric fe 23 non-motor symptom change were similar and we observed the aforementioned association
24 between motor symptoms and brain morphometric features. Therefore, we reason that our
25 findings for non-motor symptoms genuinely 24 between motor symptoms and brain morphometric features. Therefore, we reason that our
25 findings for non-motor symptoms genuinely reflect the absence of an effect rather than being
25 findings for non-motor symptoms ge 25 findings for non-motor symptoms genuinely reflect the absence of an effect rather than being
6

symptoms, 16,17

attributed to low sensitivity. As non-motor symptoms constitute a heterogeneous group of
symptoms,^{16,17} several aspects have to be considered when interpreting the present findings.
First, this study investigated the bra 2 symptoms,^{16,17} several aspects have to be considered when interpreting the present findings.

2 First, this study investigated the brain areas associated with postoperative changes in a wide

1 range of non-motor sympt First, this study investigated the brain areas associated with postoperative changes in a wide

range of non-motor symptoms assessed by the NMSS total and its domain scores. Previous

studies found limited evidence of an a range of non-motor symptoms assessed by the NMSS total and its domain scores. Previous
studies found limited evidence of an association between cortical atrophy and postoperative
changes in various cognitive functions.¹⁸ studies found limited evidence of an association between cortical atrophy and postoperative
changes in various cognitive functions.¹⁸ Lower hippocampal volume, however, has been
associated with a postoperative decline in changes in various cognitive functions.¹⁸ Lower hippocampal volume, however, has been
associated with a postoperative decline in verbal memory.^{18,19} In the present study, lower
hippocampal volumes were associated with associated with a postoperative decline in verbal memory.^{18,19} In the present study, lower
hippocampal volumes were associated with less postoperative changes in the attention and
memory domains, although these results d 8 hippocampal volumes were associated with less postoperative changes in the attention and
9 memory domains, although these results did not survive TFCE correction. The lack of
9 significant results in this domain might be 9 memory domains, although these results did not survive TFCE correction. The lack of
6 significant results in this domain might be attributed to the presumably low sensitivity of the
1 NMSS to detect subtle changes in a s independent results in this domain might be attributed to the presumably low sensitivity of the
11 NMSS to detect subtle changes in a single cognitive domain. The NMSS is a clinician-rated
12 scale investigating a wide ran 11 NMSS to detect subtle changes in a single cognitive domain. The NMSS is a clinician-rated
12 scale investigating a wide range of NMS across nine domains whereby symptoms are rated
13 according to severity and frequency. scale investigating a wide range of NMS across nine domains whereby symptoms are rated
according to severity and frequency. Thus, it is not intended to evaluate specific cognitive
domains but global cognition and to assess 213 according to severity and frequency. Thus, it is not intended to evaluate specific cognitive
214 domains but global cognition and to assess the progress or treatment response of a wide range
215 of non-motor symptoms. of non-motor symptoms.²⁰

domains but global cognition and to assess the progress or treatment response of a wide range
of non-motor symptoms.²⁰
Second, the present study investigated the association between brain morphometry and short-
term non---
16
17
18 Second, the present study investigated the association between brain morphometry and short-
17 term non-motor outcomes, not the development or worsening of pre-existing non-motor
18 symptoms, which may result from progress 17 term non-motor outcomes, not the development or worsening of pre-existing non-motor
18 symptoms, which may result from progression of Parkinson's disease rather than from
19 neurostimulation. In this context, Aybek and 18 symptoms, which may result from progression of Parkinson's disease rather than from
19 neurostimulation. In this context, Aybek and colleagues identified hippocampal volume as a
10 narker to predict postsurgical convers neurostimulation. In this context, Aybek and colleagues identified hippocampal volume as a
20 marker to predict postsurgical conversion to dementia in a long-term, i.e., 25 months, follow-
21 up.²¹ Patients with Parkinso 20 marker to predict postsurgical conversion to dementia in a long-term, i.e., 25 months, follow-
21 up.²¹ Patients with Parkinson's disease dementia had smaller preoperative hippocampal
22 volumes than patients without $up.^{21}$ 21 up.²¹ Patients with Parkinson's disease dementia had smaller preoperative hippocampal
22 volumes than patients without conversion. The authors concluded that hippocampal atrophy is
23 a potential clinical marker to pr 22 volumes than patients without conversion. The authors concluded that hippocampal atrophy is
23 a potential clinical marker to predict postoperative conversion to dementia, but that the
24 postsurgical development is due 23 a potential clinical marker to predict postoperative conversion to dementia, but that the
24 postsurgical development is due to the disease progression rather than the procedure itself.²¹
25 As the present study inves postsurgical development is due to the disease progression rather than the procedure itself.²¹ 25
26 25 As the present study investigated short-term outcomes only, further studies investigating the relationship between brain morphometry and long-term non-motor outcomes are needed. 26 relationship between brain morphometry and long-term non-motor outcomes are needed.

1 Third, it is now widely accepted that the DBS effects are mediated via mechanisms on
2 multiple levels, encompassing the micro- (e.g., local spiking activity), meso- (e.g., local field
2 potentials), and macro-scale (e.g multiple levels, encompassing the micro- (e.g., local spiking activity), meso- (e.g., local field
potentials), and macro-scale (e.g., interregional networks).²² In particular, network effects of
DBS have received increas potentials), and macro-scale (e.g., interregional networks). 22 3 potentials), and macro-scale (e.g., interregional networks).²² In particular, network effects of

4 DBS have received increasing attention in recent years, and it has been postulated that

15 integrating a patient's co 1 DBS have received increasing attention in recent years, and it has been postulated that

15 integrating a patient's connectome into surgical planning could facilitate personalised DBS

16 therapy.⁴ Non-motor outcomes f integrating a patient's connectome into surgical planning could facilitate personalised DBS
therapy.⁴ Non-motor outcomes following STN-DBS depend on the location of
neurostimulation.²² Furthermore, previous studies hav therapy.⁴ Non-motor outcomes following STN-DBS depend on the location of
neurostimulation.²² Furthermore, previous studies have associated the stimulation of specific
fibre tracts with postoperative outcomes such as de neurostimulation.²² meurostimulation.²² Furthermore, previous studies have associated the stimulation of specific
fibre tracts with postoperative outcomes such as depression and impulsivity.^{23,24} In summary,
neuromodulation of subcortical fibre tracts with postoperative outcomes such as depression and impulsivity.^{23,24} 8 fibre tracts with postoperative outcomes such as depression and impulsivity.^{23,24} In summary,
9 neuromodulation of subcortical brain regions and connected functional brain networks is
8 associated with non-motor outcom 9 neuromodulation of subcortical brain regions and connected functional brain networks is
1 associated with non-motor outcomes, whereas cortical atrophy evident in routine MRI scans is
1 not. The clinical implication of ou associated with non-motor outcomes, whereas cortical atrophy evident in routine MRI scans is
not. The clinical implication of our study is that atrophy in the prefrontal cortex should be
considered as an MRI biomarker of s not. The clinical implication of our study is that atrophy in the prefrontal cortex should be
12 considered as an MRI biomarker of subpar motor outcome of STN-DBS, whereas cortical
13 atrophy may not indicate worse non-mot considered as an MRI biomarker of subpar motor outcome of STN-DBS, whereas cortical
atrophy may not indicate worse non-motor outcomes. Compared to these metrics of
morphometry based on routine MRI examinations, it is conce atrophy may not indicate worse non-motor outcomes. Compared to these metrics of
morphometry based on routine MRI examinations, it is conceivable that more advanced
imaging techniques, e.g., markers of cerebral microstructu 14 morphometry based on routine MRI examinations, it is conceivable that more advanced
15 imaging techniques, e.g., markers of cerebral microstructure, such as neurite density, and
16 connectivity measures are more sensiti imaging techniques, e.g., markers of cerebral microstructure, such as neurite density, and
connectivity measures are more sensitive to map non-motor treatment effects.²⁵
17
Limitations connectivity measures are more sensitive to map non-motor treatment effects.²⁵

--
17
18
19

18
19
20 18 **Limitations**
19 First, despite
20 Nonetheless,
21 postoperative 19 First, despite being one of the largest cohorts of its kind, the sample size is relatively small.

20 Nonetheless, it is unlikely that our sample was underpowered because the effect size of

21 postoperative changes of 20 Nonetheless, it is unlikely that our sample was underpowered because the effect size of
21 postoperative changes of motor and non-motor symptoms was comparable (Cohen's d: .45,
22 respectively .46) and we observed an as 21 postoperative changes of motor and non-motor symptoms was comparable (Cohen's d: .45,
22 respectively .46) and we observed an association between metrics of morphometry and motor,
23 but not non-motor outcomes. Second, respectively .46) and we observed an association between metrics of morphometry and motor,
but not non-motor outcomes. Second, we did not employ scales that specifically measure
certain motor and non-motor symptoms, such a 23 but not non-motor outcomes. Second, we did not employ scales that specifically measure
24 certain motor and non-motor symptoms, such as the Bain and Findley tremor scale for tremor,
25 the Parkinson's disease Sleep Scal 24 certain motor and non-motor symptoms, such as the Bain and Findley tremor scale for tremor,
25 the Parkinson's disease Sleep Scale (PDSS) for sleep, or the Montreal Cognitive Assessment
26 (MoCA) for cognitive symptoms 25 the Parkinson's disease Sleep Scale (PDSS) for sleep, or the Montreal Cognitive Assessment
26 (MoCA) for cognitive symptoms as we were interested in the association between brain
26 26 (MoCA) for cognitive symptoms as we were interested in the association between brain 8

1 morphometry and global motor and non-motor symptom burden. Therefore, we chose the
2 UPDRS-III and the NMSS-T, which represent composite scores for motor and non-motor
3 symptom severity. Furthermore, we wanted to ensure 2 UPDRS-III and the NMSS-T, which represent composite scores for motor and non-motor
3 symptom severity. Furthermore, we wanted to ensure consistency with prior studies
4 employing the UPDRS-III as an outcome parameter. Th 3 symptom severity. Furthermore, we wanted to ensure consistency with prior studies
4 employing the UPDRS-III as an outcome parameter. Third, the exact scanning parameters
5 (e.g., repetition-time (TR) and echo-time (TE)) 4 employing the UPDRS-III as an outcome parameter. Third, the exact scanning parameters (e.g., repetition-time (TR) and echo-time (TE)) differed slightly across the sample. In a previous study, however, our group demonstr (e.g., repetition-time (TR) and echo-time (TE)) differed slightly across the sample. In a
previous study, however, our group demonstrated that results remained consistent even after
integrating scanning parameters into the 6 previous study, however, our group demonstrated that results remained consistent even after
integrating scanning parameters into the regression analysis.²⁶
8 integrating scanning parameters into the regression analysis.²⁶

-
8
9

9
0 9 **Conclusion**
20 Our study supports the importance of intact superior frontal cortex integrity as a predictor for
21 motor outcomes in PD patients undergoing STN-DBS. Despite several advantages, including
22 being based o 10 Our study supports the importance of intact superior frontal cortex integrity as a predictor for
11 motor outcomes in PD patients undergoing STN-DBS. Despite several advantages, including
12 being based on scans impleme motor outcomes in PD patients undergoing STN-DBS. Despite several advantages, including
12 being based on scans implemented as a standard preoperative procedure, the short scanning
13 time, and established pipelines in ana 12 being based on scans implemented as a standard preoperative procedure, the short scanning
13 time, and established pipelines in analysing and interpreting findings, our results indicate that
14 the use of VBM as a measu time, and established pipelines in analysing and interpreting findings, our results indicate that
the use of VBM as a measure to inform the patient selection and preoperative counselling is
limited to motor effects and doe 14 the use of VBM as a measure to inform the patient selection and preoperative counselling is
15 limited to motor effects and does not extend to non-motor effects of STN-DBS.
16 15 limited to motor effects and does not extend to non-motor effects of STN-DBS.
16
17 **Methods**

--
17
18

17 **Methods**
18 **Participant:**
19 Patients were 18 **Participants**
19 Patients were e
20 consent in a si
21 on the UK Bra Patients were enrolled in this prospective, observational, ongoing study upon written informed

20 consent in a single centre (University Hospital Cologne). Clinical diagnosis of PD was based

21 on the UK Brain Bank Crite 20 consent in a single centre (University Hospital Cologne). Clinical diagnosis of PD was based
21 on the UK Brain Bank Criteria, and indication for DBS surgery was established according to
22 international guidelines.^{27,} 21 on the UK Brain Bank Criteria, and indication for DBS surgery was established according to
22 international guidelines.^{27,28} Exclusion criteria comprised pathological MR imaging, clinically
23 relevant cognitive impai international guidelines.^{27,28} 22 international guidelines.^{27,28} Exclusion criteria comprised pathological MR imaging, clinically
23 relevant cognitive impairments, and impaired visual and auditory function. The study was
23 relevant cognitive impair 23 relevant cognitive impairments, and impaired visual and auditory function. The study was

2 **2 Clinical Assessment**
2 **ethics committee (study no.: 12-145)**
2 Clinical assessments were conducted at the preoperative baseline in the ON-medication state 4
5
6 4 **Clinical Assessment**
5 Clinical assessments we
6 (MedON) and six mol
7 (MedON/StimON). Sta 5 Clinical assessments were conducted at the preoperative baseline in the ON-medication state
6 (MedON) and six months after DBS surgery in the ON-medication/ON-stimulation state
6 (MedON/StimON). Standardised case report 6 (MedON) and six months after DBS surgery in the ON-medication/ON-stimulation state

(MedON/StimON). Standardised case report forms were used to collect demographic and

clinical data on both study visits, including a com 7 (MedON/StimON). Standardised case report forms were used to collect demographic and
8 clinical data on both study visits, including a comprehensive neuropsychological assessment
9 which comprised the following scales:
10

11 (1) The Non-motor Symptoms Scale (NMSS) is a scale evaluated by clinicians that 9 which comprised the following scales:
0
1 (1) The Non-motor Symptoms Sc
2 consists of 30 items, which asse --
11
12
13 12 consists of 30 items, which assess nine domains of non-motor symptoms, including (1)
13 cardiovascular, (2) sleep/fatigue, (3) mood/apathy, (4) perceptual
14 problems/hallucinations, (5) attention/memory, (6) gastrointe consists of 30 items, which assess nine domains of non-motor symptoms, including (1)
cardiovascular, (2) sleep/fatigue, (3) mood/apathy, (4) perceptual
problems/hallucinations, (5) attention/memory, (6) gastrointestinal tr 15 (8) sexual function, and (9) miscellaneous. The miscellaneous category includes
16 questions regarding pain, the ability to smell/taste, weight change, and excessive problems/hallucinations, (5) attention/memory, (6) gastrointestinal tract, (7) urinary,

15 (8) sexual function, and (9) miscellaneous. The miscellaneous category includes

16 questions regarding pain, the ability to smell 15 (8) sexual function, and (9) miscellaneous. The miscellaneous category includes
16 questions regarding pain, the ability to smell/taste, weight change, and excessive
17 sweating. The NMSS has been frequently used in DB questions regarding pain, the ability to smell/taste, weight change, and excessive
sweating. The NMSS has been frequently used in DBS studies for PD.²⁹⁻³¹ The score
on this scale ranges from 0, indicating no impairment, sweating. The NMSS has been frequently used in DBS studies for PD.²⁹⁻³¹ sweating. The NMSS has been frequently used in DBS studies for PD.²⁹⁻³¹ The score

on this scale ranges from 0, indicating no impairment, to 360, indicating maximum

impairment, while the symptoms are evaluated over the on this scale ranges from 0, indicating no impairment, to 360, indicating maximum

19 impairment, while the symptoms are evaluated over the past four weeks.²⁰

20 (2) The PD Questionnaire (PDQ)-8 is a self-reported short impairment, while the symptoms are evaluated over the past four weeks. 20

20
21
22 20 (2) The PD Questionnaire (PDQ)-8 is a self-reported short form of the PDQ-39 that
21 assesses eight dimensions of quality of life (QoL) in patients with PD. The PDQ-8 has
22 been frequently used in DBS studies for PD.³ 21 assesses eight dimensions of quality of life (QoL) in patients with PD. The PDQ-8 has
22 been frequently used in DBS studies for PD.³²⁻³⁴ The scale is reported as a summary
23 index (SI) and ranges from 0, indicating been frequently used in DBS studies for PD.³²⁻³⁴ 22 been frequently used in DBS studies for PD.³²⁻³⁴ The scale is reported as a summary

23 index (SI) and ranges from 0, indicating no impairment, to 100, indicating maximum

24 impairment.^{2,35,36} 23 index (SI) and ranges from 0, indicating no impairment, to 100, indicating maximum
24 impairment. $2,35,36$ impairment. 2,35,36

13 a single centre (Cologne). Each PD patient in the MedON underwent a 3D T1-weighted
14 Magnetization Prepared - RApid Gradient Echo sequence (MPRAGE) at baseline.
15 At the time of image acquisition, images were investig 14 Magnetization Prepared - RApid Gradient Echo sequence (MPRAGE) at baseline.
15 At the time of image acquisition, images were investigated to be free of motion
16 and high frequency or wrap-around artefacts.
17 15 At the time of image acquisition, images were investigated to be free of motion or ghosting
16 and high frequency or wrap-around artefacts.
17
18 **Image Processing** 26 and high frequency or wrap-around artefacts.
17
18 Image Processing
19 Voxel-based morphometry was performed within the Computational Anatomy Toolbox

--
18
19
20 18 **Image Processing**
19 Voxel-based morph
20 (CAT) analysis suite
21 Statistical Parametric 19 Voxel-based morphometry was performed within the Computational Anatomy Toolbox
20 (CAT) analysis suite (CAT12.8.2, University Hospital Jena, Jena, Germany)³⁹ implemented in
21 Statistical Parametric Mapping 12 (SPM12, (CAT) analysis suite (CAT12.8.2, University Hospital Jena, Jena, Germany)³⁹ (CAT) analysis suite (CAT12.8.2, University Hospital Jena, Jena, Germany)³⁹ implemented in
21 Statistical Parametric Mapping 12 (SPM12, Wellcome Department of Cognitive Neurology,
22 London, United Kingdom). All steps we 21 Statistical Parametric Mapping 12 (SPM12, Wellcome Department of Cognitive Neurology,
22 London, United Kingdom). All steps were conducted in MATLAB R2022a (The MathWorks
23 Inc., Natick, MA, USA), as reported previousl 22 London, United Kingdom). All steps were conducted in MATLAB R2022a (The MathWorks
23 Inc., Natick, MA, USA), as reported previously by Jergas et al.²⁶ In short, processing included
24 spatial registration to a templat Inc., Natick, MA, USA), as reported previously by Jergas et al.²⁶ Inc., Natick, MA, USA), as reported previously by Jergas et al.²⁶ In short, processing included
24 spatial registration to a template brain, segmentation into cortical grey matter, white matter,
25 and cerebrospinal flui 24 spatial registration to a template brain, segmentation into cortical grey matter, white matter,
25 and cerebrospinal fluid, calculation of total intracranial volume (TIV), and empirical quality
21 25 and cerebrospinal fluid, calculation of total intracranial volume (TIV), and empirical quality
11

1 control (QC) using default parameters. QC was performed within the QC framework of
2 CAT12 with scans not rating lower than B-. Finally, data smoothing was performed using an
8 mm full-width half-maximum isotropic Gaussi 2 CAT12 with scans not rating lower than B-. Finally, data smoothing was performed using an
3 8 mm full-width half-maximum isotropic Gaussian kernel.
4 Statistical analysis

3 **Statistical analysis**
3 Statistical analysis of clinical outcomes was performed using MATLAB R2018b. We $\frac{5}{7}$ 5 **Statistical analysis**
6 Statistical analysis c
7 employed the Shapi
8 Wilcoxon signed-rank 6 employed the Shapiro-Wilk test to assess the assumption of normality. Subsequently,
8 Wilcoxon signed-rank- or t-tests, when parametric test criteria were fulfilled, were employed
9 to analyse changes between baseline an 7 Wilcoxon signed-rank- or t-tests, when parametric test criteria were fulfilled, were employed
10 to analyse changes between baseline and 6-month follow-up. The Benjamini-Hochberg
10 method was used to control the false d 8 Wilcoxon signed-rank- or t-tests, when parametric test criteria were fulfilled, were employed

6 to analyse changes between baseline and 6-month follow-up. The Benjamini-Hochberg

1 to Cohen.^{40,41} Reported p-values ar 9 to analyse changes between baseline and 6-month follow-up. The Benjamini-Hochberg

0 method was used to control the false discovery rate and effect sizes were calculated according

1 to Cohen.^{40,41} Reported p-values a method was used to control the false discovery rate and effect sizes were calculated according
to Cohen.^{40,41} Reported p-values are two-sided and were accepted as significant where p<.05.
Statistical voxelwise analysis o to Cohen. $40,41$ to Cohen.^{40,41} Reported p-values are two-sided and were accepted as significant where $p<.05$.

Statistical voxelwise analysis of image data was performed using SPM12. Here, clinica

outcomes were represented as change 12 Statistical voxelwise analysis of image data was performed using SPM12. Here, clinical
13 outcomes were represented as change scores in UPDRS-III, NMSS-T, and NMSS-Domains
14 and calculated according to the following e 13 outcomes were represented as change scores in UPDRS-III, NMSS-T, and NMSS-Domains
14 and calculated according to the following equation:
 $Scale_{baseline} - Scale_{follow-up}$
15 Associations between surrogates of brain morphometry and motor an

$\frac{1}{2}$ calculations $\frac{1}{2}$ calculations $\frac{1}{2}$

214 and calculated according to the following equation:
 $Scale_{baseline} - Sca$

215 Associations between surrogates of brain morphon

216 were assessed using a multiple regression analysis v 15 Associations between surrogates of brain morphometry and motor and non-motor outcomes
16 were assessed using a multiple regression analysis with age, sex, and total intracranial volume
17 as covariates. A threshold-free were assessed using a multiple regression analysis with age, sex, and total intracranial volume
as covariates. A threshold-free cluster enhancement (TFCE) was applied to correct for
multiple comparisons as implemented in t 17 as covariates. A threshold-free cluster enhancement (TFCE) was applied to correct for multiple comparisons as implemented in the TFCE Toolbox. Results were accepted as significant where family-wise error corrected p<.05 multiple comparisons as implemented in the TFCE Toolbox. Results were accepted as
significant where family-wise error corrected p<.05.
20 19 significant where family-wise error corrected p<.05.
20
21 Acknowledgement

--
21
22

21 **Acknowledgement**
22 The authors thank the participants for their active engagement in this study.
23 22 The authors thank the participants for their active engagement in this study.
23

Data and Code Availability
2 The data supporting this study's findings are available on reasonable request from the
3 corresponding authors (PAL, HSD). The data are not publicly available due to privacy or
4 ethical rest 2 The data supporting this study's findings are available on reasonable request from the corresponding authors (PAL, HSD). The data are not publicly available due to privacy or ethical restrictions. All tools used to analy 3 corresponding authors (PAL, HSD). The data are not publicly available due to privacy or
ethical restrictions. All tools used to analyse MRI data are based on CAT12 (https://neuro-
jena.github.io/cat/) and SPM12 (http://w ethical restrictions. All tools used to analyse MRI data are based on CAT12 (https://neuro-
jena.github.io/cat/) and SPM12 (http://www.fil.ion.ucl.ac.uk/spm).
6 5 jena.github.io/cat/) and SPM12 (http://www.fil.ion.ucl.ac.uk/spm).
6
7 **Contributorship**

7
8

7 Contributorship
8 PAL: study concept and design, data acquisition, data an
9 WS: data acquisition, critical revision of the manuscript
10 STJ: data acquisition, critical revision of the manuscript 8 PAL: study concept and design, data acquisition, data analysis, drafting of the manuscript
WS: data acquisition, critical revision of the manuscript
STJ: data acquisition, critical revision of the manuscript
MS: critical

-
- 9 10 STJ: data acquisition, critical revision of the manuscript

9 MS: critical revision of the manuscript

9 JNPS: data acquisition, critical revision of the manuscript
-
- 11 MS: critical revision of the manuscript
12 JNPS: data acquisition, critical revision
13 AS: data acquisition, critical revision of
14 AG: data acquisition, critical revision of
- 13 AS: data acquisition, critical revision of the manuscript
-
- 12 JNPS: data acquisition, critical revision of the manuscript
13 AS: data acquisition, critical revision of the manuscript
14 AG: data acquisition, critical revision of the manuscript
15 VVV: data acquisition, surgical in 13 AS: data acquisition, critical revision of the manuscript
14 AG: data acquisition, critical revision of the manuscript
15 VVV: data acquisition, surgical intervention, critical rev
16 GRF: critical revision of the manus 14 AG: data acquisition, critical revision of the manuscript
15 VVV: data acquisition, surgical intervention, critical revision of the manuscript
16 GRF: critical revision of the manuscript
17 JE: critical revision of the 15 VVV: data acquisition, surgical intervention, critical revision of the manuscript
16 GRF: critical revision of the manuscript
17 JE: critical revision of the manuscript
18 MK: data acquisition, critical revision of the
-
-
- 17 JE: critical revision of the manuscript
18 MK: data acquisition, critical revision of the manuscript
19 AR: critical revision of the manuscript 18 MK: data acquisition, critical revision of the manuscript

19 AR: critical revision of the manuscript

20 AA: critical revision of the manuscript

21 KA: critical revision of the manuscript
- 17 JE: critical revision of the manuscript
18 MK: data acquisition, critical revision
19 AR: critical revision of the manuscrip
20 AA: critical revision of the manuscrip
-
-
- 19 AR: critical revision of the manuscript
20 AA: critical revision of the manuscript
21 KA: critical revision of the manuscript
22 PMM: critical revision of the manuscript 20 AA: critical revision of the manuscript
21 KA: critical revision of the manuscript
22 PMM: critical revision of the manuscript
23 CG: critical revision of the manuscript 21 KA: critical revision of the manuscript
22 PMM: critical revision of the manuscript
23 CG: critical revision of the manuscript
24 KRC: critical revision of the manuscrip
-
- 22 PMM: critical revision of the manuscript
23 CG: critical revision of the manuscript
24 KRC: critical revision of the manuscript
25 LT: study concept and design, critical rev 23 CG: critical revision of the manuscript
24 KRC: critical revision of the manuscript
25 LT: study concept and design, critical r 24 KRC: critical revision of the manuscript
25 LT: study concept and design, critical rev
- 25 LT: study concept and design, critical revision of the manuscript
 $\frac{1}{2}$
-
- 1 JCB: study concept and design, data acquisition, data analysis, drafting of the manuscript

1 HSD: study concept and design, data acquisition, data analysis, drafting of the manuscript

1 3 2 HSD: study concept and design, data acquisition, data analysis, drafting of the manuscript
3
4 Financial disclosure/Conflicts of Interest
-

-
4
5

- **Financial disclosure/Conflicts of Interest**

PAL was supported by the SUCCESS-Program of the Philipps-University of Marburg, the

Stiftung zur Förderung junger Neurowissenschaftler', and the Prof. Klaus Thiemann

Foundati
-

9 PAL was supported by the SUCCESS-Program of the Philipps-University of Marburg, the

5 'Stiftung zur Förderung junger Neurowissenschaftler', and the Prof. Klaus Thiemann

7 Foundation in the German Society of Neurology.
 5 'Stiftung zur Förderung junger Neurowissenschaftler', and the Prof. Klaus Thiemann
5 Foundation in the German Society of Neurology.
8 WS was supported by the Koeln Fortune Program/Faculty of Medicine, University of Colog WS was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne
and reports no financial relationships with commercial interests.
10 STJ was funded by the Prof. Klaus Thiemann Foundation and the Br

-
- WS was supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne
and reports no financial relationships with commercial interests.
STJ was funded by the Prof. Klaus Thiemann Foundation and the Brand 9 and reports no financial relationships with commercial interests.

9 STJ was funded by the Prof. Klaus Thiemann Foundation

1 Foundation, outside of the submitted work.

2 MS has received honoraria from Bial, Britannia a
-
-
- 10 STJ was funded by the Prof. Klaus Thiemann Foundation and the Brandau-Laibach-
11 Foundation, outside of the submitted work.
12 MS has received honoraria from Bial, Britannia and Medtronic.
13 JNPS funded by the Cologne 11 Foundation, outside of the submitted work.
12 MS has received honoraria from Bial, Brita
13 JNPS funded by the Cologne Clinician
14 University of Cologne; and by the German 12 MS has received honoraria from Bial, Britannia and Medtronic.
13 JNPS funded by the Cologne Clinician Scientist Program (
14 University of Cologne; and by the German Research Foundation
15 AS reports no financial disclo
- INPS funded by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/

University of Cologne; and by the German Research Foundation (DFG, FI 773/15-464 1).

AS reports no financial disclosures.

AG reports no 14 University of Cologne; and by the German Research Foundation (DFG, FI 773/15-464 1).
15 AS reports no financial disclosures.
16 AG reports no financial disclosures.
17 VVV reports compensation for contributions to advis
-

15 AS reports no financial disclosures.
16 AG reports no financial disclosures.
17 VVV reports compensation for
18 Medtronic, Boston Scientific, and Li 16 AG reports no financial disclosures.
17 VVV reports compensation for a
18 Medtronic, Boston Scientific, and Li
19 GRF serves as an editorial board r

18 Medtronic, Boston Scientific, and Livanova.
19 GRF serves as an editorial board member of Cortex, Neurological Research and Practice,
20 Neurolmage: Clinical, Zeitschrift für Neuropsychologie, DGNeurologie, and Info Neu 18 Medtronic, Boston Scientific, and Livanova.
19 GRF serves as an editorial board member
20 Neurolmage: Clinical, Zeitschrift für Neurop
21 & Psychiatrie; receives royalties from the 19 GRF serves as an editorial board member of Cortex, Neurological Research and Practice,
20 Neurolmage: Clinical, Zeitschrift für Neuropsychologie, DGNeurologie, and Info Neurologie
21 & Psychiatrie; receives royalties fr 20 NeuroImage: Clinical, Zeitschrift für Neuropsychologie, DGNeurologie, and Info Neurologie
21 & Psychiatrie; receives royalties from the publication of the books Funktionelle MRT in
22 Psychiatrie und Neurologie, Neurolo 21 & Psychiatrie; receives royalties from the publication of the books Funktionelle MRT in
22 Psychiatrie und Neurologie, Neurologische Differentialdiagnose, and SOP Neurologie;
23 receives royalties from the publication o 22 Psychiatrie und Neurologie, Neurologische Differentialdiagnose, and SOP Neurologie;
23 receives royalties from the publication of the neuropsychological tests KAS and Köpps;
24 received honoraria for speaking engagement receives royalties from the publication of the neuropsychological tests KAS and Köpps;

received honoraria for speaking engagements from Deutsche Gesellschaft für Neurologie

(DGN) and Forum für medizinische Fortbildung Fo 24 received honoraria for speaking engagements from Deutsche Gesellschaft für Neurologie
25 (DGN) and Forum für medizinische Fortbildung FomF GmbH.
24 25 (DGN) and Forum für medizinische Fortbildung FomF GmbH.

1 JE reports no financial disclosures.

2 MK was funded by the KoelnFortune program of the Medical Faculty of the University of

1 Cologne and reports no financial relationships with commercial interests.

4 AR received fu

2 MK was funded by the KoelnFortune program of the Medical Faculty of the University of
2 Cologne and reports no financial relationships with commercial interests.
2 AR received funding from the National Institute for Heal 3 Cologne and reports no financial relationships with commercial interests.
4 AR received funding from the National Institute for Health and Care R
5 Clinical Research Network (CRN) South London, and grant funding fro
6 Pa

4 5 Clinical Research Network (CRN) South London, and grant funding from the International
16 Parkinson and Movement Disorders Society (MDS).
17 AA received compensation for consultancy and speaker-related activities from

5 Clinical Research Network (CRN) South London, and grant funding from the International
6 Parkinson and Movement Disorders Society (MDS).
7 AA received compensation for consultancy and speaker-related activities from UCB,

9 Parkinson and Movement Disorders Society (MDS).

2 AA received compensation for consultancy and

2 Boehringer Ingelheim, Ever Pharma, General Elec

2 Zambon, Bial, Theravance Biopharma, Jazz Pharma 7 AA received compensation for consultancy and speaker-related activities from UCB,
8 Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin,
7 Zambon, Bial, Theravance Biopharma, Jazz Pharmace

8 Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin,
2 Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, Medscape. He receives
1 esearch support from Bial, Lundbeck, Roche, 9 Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, Medscape. He receives
10 research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grant
12 825785, Horizon 2020 Grant 101016902, 11 825785, Horizon 2020 Grant 101016902, Ministry of Education University and Research
12 (MIUR) Grant ARS01_01081, Cariparo Foundation, Movement Disorders Society for NMS
13 Scale validation. He serves as consultant for B

- 11 825785, Horizon 2020 Grant 101016902, Ministry of Education University and Research
12 (MIUR) Grant ARS01_01081, Cariparo Foundation, Movement Disorders Society for NMS
13 Scale validation. He serves as consultant for B 12 (MIUR) Grant ARS01_01081, Cariparo Foundation, Movement Disorders Society for NMS
13 Scale validation. He serves as consultant for Boehringer–Ingelheim for legal cases on
14 pathological gambling.
15 KA has received hon
-

14 pathological gambling.
15 KA has received honoraria for educational meetings, travel and consultancy from Medtronic,
16 St. Jude Medical and Boston Scientific.

14 pathological gambling.
15 KA has received honor.
16 St. Jude Medical and Bo
17 PMM received honorar 17 PMM received honoraria from the International Parkinson and Movement Disorder Society
18 (IPMDS) for management of the Clinical Outcome Assessment Program. 16 St. Jude Medical and Boston Scientific.
17 PMM received honoraria from the Inte
18 (IPMDS) for management of the Clinica
19 CG reports no financial disclosures.

17 PMM received honoraria from the International Parkinson and Movement Disorder Society
18 (IPMDS) for management of the Clinical Outcome Assessment Program.
19 CG reports no financial disclosures.
19 KRC received grants 18 (IPMDS) for management of the Clinical Outcome Assessment Program.
19 CG reports no financial disclosures.
19 KRC received grants (IIT) from Britannia Pharmaceuticals, AbbVie, UCE
21 2020, Parkinson's UK, NIHR, Parkinso CG reports no financial disclosures.

20 KRC received grants (IIT) from Brit

21 2020, Parkinson's UK, NIHR, P.

22 Foundation, MRC; royalties or lice 20 KRC received grants (IIT) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, EU Horizon
2020, Parkinson's UK, NIHR, Parkinson's Foundation, Wellcome Trust, Kirby Laing
22 Foundation, MRC; royalties or licenses from Oxfor 22 Foundation, MRC; royalties or licenses from Oxford (book), Cambridge publishers (book),
23 MAPI institute (KPPS, PDSS 2); consulting fees, support for attending meetings or travel, and
24 Darticipated on data safety mon MAPI institute (KPPS, PDSS 2); consulting fees, support for attending meetings or travel, and 23 MAPI institute (KPPS, PDSS 2); consulting fees, support for attending meetings or travel, and
24 participated on data safety monitoring board or advisory board for AbbVie, UCB, GKC, Bial, 24 participated on data safety monitoring board or advisory board for AbbVie, UCB, GKC, Bial,

 43

1 **Tables**
2 **Table 1: I**

2 **Table 1: Baseline characteristics and outcomes at baseline and 6-month follow-up**
N M SD

Table 1: Demographic characteristics and outcome parameters at baseline and 6-month
follow-up. Reported p-values are corrected for multiple comparisons using Benjamini-
Hochberg's method (six scales). Bold font highlight follow-up. Reported p-values are corrected for multiple comparisons using Benjamini-
Hochberg's method (six scales). Bold font highlights significant results, $p < .05$.
Abbreviations: 6-MFU = 6-month follow-up; LEDD = Le 5 Hochberg's method (six scales). Bold font highlights significant results, p<.05.
 Abbreviations: 6-MFU = 6-month follow-up; LEDD = Levodopa equivale

LEDD-DA: LEDD of dopamine agonists; NMSS = Non-Motor Symptom Scal 6 **Abbreviations:** 6-MFU = 6-month follow-up; LEDD = Levodopa equivalent daily dose;

LEDD-DA: LEDD of dopamine agonists; NMSS = Non-Motor Symptom Scale; PDQ-8 SI =

19

7 LEDD-DA: LEDD of dopamine agonists; NMSS = Non-Motor Symptom Scale; PDQ-8 SI = 19

-
- 1 8-item Parkinson's Disease Questionnaire Summary Index; SCOPA-M = Scales for Outcomes

2 in Parkinson's disease-Motor; SD = Standard deviation, UPDRS III = Unified Parkinson's

1 Disease Rating Scale Part III

4

5 2 in Parkinson's disease-Motor; SD = Standard deviation, UPDRS III = Unified Parkinson's
3 Disease Rating Scale Part III
4
5 **Table 2: Association between brain morphometry and UPDRS-III**
-
-
- 5
6
6

6
1 6 **Table 2: Association between brain morphometry and UPDRS-III**

Table 2. Characteristics of clusters with an association between metrics of voxel-based
amorphometry and postoperative change in UPDRS-III. "Cluster" denotes clusters with a
significant association between grey matter loss 8 morphometry and postoperative change in UPDRS-III. "Cluster" denotes clusters with a significant association between grey matter loss and poor motor response to deep brain stimulation (DBS). "Location" indicates the anat 9 significant association between grey matter loss and poor motor response to deep brain
0 stimulation (DBS). "Location" indicates the anatomical landmark comprising the majority of
1 voxels of a cluster, according to the 10 stimulation (DBS). "Location" indicates the anatomical landmark comprising the majority of
11 voxels of a cluster, according to the Desikan-Killiany Atlas. P-Values are clusterwise p-values
12 corrected for multiple com 11 voxels of a cluster, according to the Desikan-Killiany Atlas. P-Values are clusterwise p-values

12 corrected for multiple comparisons. "MNI152-coordinates" describe the coordinates of the

13 cluster's center of gravit 12 corrected for multiple comparisons. "MNI152-coordinates" describe the coordinates of the

13 cluster's center of gravity in MNI152-space.

14

15 13 cluster's center of gravity in MNI152-space.
14
15
16

 15
 16 --
16

 $\overline{2}$

Figure 1. Visualisation of baseline and 6-month follow-up values of the Unified Parkinson's

Disease Rating Scale-part III (A) and Non-Motor Symptom Scale-total score (B).

5

3
4
5 4 Disease Rating Scale-part III **(A)** and Non-Motor Symptom Scale-total score **(B)**.

6
5
1

 $\mathbf{1}$

-
2
3
4
5 **2 Figure 2.** Clusters with an association between metrics of voxel-based morphometry and postoperative change in UPDRS-III as revealed by the whole brain analysis. Results are displayed as surface overlays. Clusters deno 3 postoperative change in UPDRS-III as revealed by the whole brain analysis. Results are displayed as surface overlays. Clusters denote regions of grey matter loss significantly associated with poor motor response to deep 4 displayed as surface overlays. Clusters denote regions of grey matter loss significantly associated with poor motor response to deep brain stimulation. P-Values were corrected for multiple comparisons using a permutatio 5 associated with poor motor response to deep brain stimulation. P-Values were corrected for multiple comparisons using a permutation-based approach and thresholded at $p<.05$, family-wise error-corrected. 6 multiple comparisons using a permutation-based approach and thresholded at $p<.05$, family-
wise error-corrected. 7 wise error-corrected.